Alzheimer's Disease
Also known as: AD
Methodology & AI Transparency ⓘ
Alzheimer's Disease Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is Alzheimer's disease? Alzheimer's disease (AD) is the most common form of dementia among older people.
- 2 Real-world patient consensus: Clinical coding for Alzheimer's Disease uses ICD-10 G30.9 across Memory & Cognition specialty care.
- 3 Typical cash cost range: Clinicians assessing Alzheimer's Disease focus on neuroinflammatory microglial activation [Alzheimer's Disease G30.9] and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Alzheimer's Disease: TSH & Fasting in Alzheimer's Disease (G30.9: ApoB / HbA1c) (Optimal cardiometabolic neuroprotection (G30.9)) and MoCA Cognitive Screening in Alzheimer's Disease (G30.9: Score).
Ask our AI Specialists anything about Alzheimer's Disease
What Is Alzheimer's Disease?
What is Alzheimer's disease? Alzheimer's disease (AD) is the most common form of dementia among older people. Dementia is a brain disorder that seriously affects thinking and memory skills. If you have AD, it can impair your ability to reason or learn new skills until it becomes difficult to complete daily activities. AD begins slowly over many years. It first involves the parts of the brain that control thought, memory, and language. It may be mistaken for normal memory changes with aging. However, AD is not a normal part of aging. The brain changes from the disease lead to symptoms that get worse over time.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Alzheimer's Disease (ICD-10 G30.9) is driven by neuroinflammatory microglial activation [Alzheimer's Disease G30.9]; Cross-referenced with NIH MeSH (Alzheimer Vaccines, Alzheimer Disease), specialists in Alzheimer, Dementia & Memory Health monitor MoCA Cognitive Screening in Alzheimer's Disease (G30.9: Score) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Getting lost in familiar places
- • Repeating the same question
- • Presentation of Alzheimer's Disease (G30.9): slowed processing speed in Alzheimer's Disease (G30.9: compared with prior)
- • Secondary Alzheimer's Disease clinical sign: short-term recall difficulty in Alzheimer's Disease (G30.9: for recent conversations,)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Alzheimer's Disease Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G30.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Alzheimer, Dementia & Memory Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: TSH & Fasting in Alzheimer's Disease (G30.9: ApoB / HbA1c) | Optimal cardiometabolic neuroprotection (G30.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: MoCA Cognitive Screening in Alzheimer's Disease (G30.9: Score) | >= 26 / 30 (G30.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Homocysteine & Vitamin in Alzheimer's Disease (G30.9: B12) | Homocysteine < 9 umol/L; B12 > 500 pg/mL (G30.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Alzheimer's Disease
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Lecanemab Leqembi • RxCUI 2626147 | Amyloid Beta-directed Antibody | 87% | $2.9700 | $ 128.79 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Alzheimer's Disease)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, gold-standard: What a 1,795-Participant Study Found Lecanemab was associated with a relative preservation of HRQoL and less increase in caregiver burden, with consistent benefits seen across different quality of life scales and within scale subdomains. The journal of prevention of Alzheimer's disease • 2023-01-15 • Phase III Randomized Trial | N = 1,795 | 96/100 | PMID 37874099 ↗ |
| New Insights on Donanemab in preclinical Alzheimer's disease: Screening and baseline data from: What a 63,124-Participant Study Found Participants 55-80 years of age were screened (N = 63,124). Alzheimer's & dementia : the journal of the Alzheimer's Association • 2025-09-15 • Phase III Randomized Trial | N = 63,124 | 96/100 | PMID 40955720 ↗ |
| Can This Approach Help? Inside the Latest Research on A small-molecule TREM2 agonist for Alzheimer’s Nature Medicine, Published online: 29 October 2026; doi:10.1038/d41591-026-00055-x Preclinical analysis and a phase 1 trial support VG-3927 as a promising drug candidate for Alzheimer’s disease, demonstrating successful penetration of the central nervous syste Nature Medicine • 2026-10-29 • Peer-Reviewed Journal (Longevity & Biotech) | Multi-cohort | 96/100 | PMID NATURE_MED-2455937869 ↗ |
| New Insights on Benefits and safety of a novel, extended-release rivastigmine transdermal patch: What a 362-Participant Study Found However, analysis of the per-protocol set demonstrated a. Journal of Alzheimer's disease : JAD • 2026-01-15 • Phase III Randomized Trial | N = 362 | 93/100 | PMID 41364455 ↗ |
| New Insights on Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and: What a 545-Participant Study Found If the primary end points are met, the data will provide confirmatory evidence of the clinical and biomarker benefits of hydromethylthionine mesylate in minimal to moderate AD. The journal of prevention of Alzheimer's disease • 2022-01-15 • Phase III Randomized Trial | N = 545 | 93/100 | PMID 36281683 ↗ |
Alzheimer's Disease Patient Community & “People Like Me” Threads
Filter Alzheimer's Disease community threads and patient logs by age, biological sex, dosage, and treatment duration.